Supplementary Figure 7: Treatment with anti-PD-1 or combination anti-PD-1 plus anti-CTLA-4 increases the relative abundance of terminally exhausted cells in the tumor. | Nature Immunology

Supplementary Figure 7: Treatment with anti-PD-1 or combination anti-PD-1 plus anti-CTLA-4 increases the relative abundance of terminally exhausted cells in the tumor.

From: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Supplementary Figure 7

a, Cell number/mg tumor of total tetramer+ CD8+ T cells from isotype control or anti-PD-1 treated B16-OVA tumors. Summary of two independent experiments, n = 13 mice. b, Frequency of progenitor exhausted (Tcf1+Tim-3–) and terminally exhausted (Tcf1–Tim-3+) PD-1+CD44+ CD8+ T cells from isotype control or anti-PD-1 treated B16-OVA tumors. Representative flow plots (left) and summary (right) of three independent experiments, n = 17 (control tx) or 15 (anti-PD-1 tx) mice. c, Cell number/mg tumor of progenitor exhausted and terminally exhausted CD8+ T cells from isotype control or anti-PD-1 treated B16-OVA tumors, gated on tetramer+ cells. Summary of two independent experiments, n = 13 mice. d, Growth curves of B16-OVA tumors treated with 100µg anti-PD-1 +/- 100µg anti-CTLA-4 or isotype control antibodies on days 9 and 12. One of two representative experiments, n = 6 mice (anti-PD-1 + anti-CDTL-4 tx), 7 mice (anti-PD-1 tx), or 8 mice (control tx). e, Summary of the frequency of progenitor exhausted and terminally exhausted cells from one of two representative experiments, n = 6 mice (anti-PD-1 + anti-CDTL-4 tx), 7 mice (anti-PD-1 tx), or 8 mice (control tx). Mean +/- s.e.m. (d); Mean +/- s.d. (a-c, e); two-sided Student’s t test (a-e); n.s. p > 0.05, * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001.

Back to article page